MX2018009861A - Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. - Google Patents

Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.

Info

Publication number
MX2018009861A
MX2018009861A MX2018009861A MX2018009861A MX2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A MX 2018009861 A MX2018009861 A MX 2018009861A
Authority
MX
Mexico
Prior art keywords
novel
substituted thiophene
protein kinase
kinase inhibitor
thiophene compound
Prior art date
Application number
MX2018009861A
Other languages
English (en)
Inventor
Beom Son Jung
Bo Sim Tae
Young Hur Woo
Man Song Chi
Jong Yoon Ho
Hye Choi Seung
Na Cho Han
Geun Choi Hwan
Doo Kim Nam
Hwa Ko Eun
Kyoung Kim Hyun
Heui Cho Joong
Yong Kang Seock
Young Kim So
Kyung Ko Yi
Yeon Lee Seung
Kyoon Yoon Suk
Hyun Bae Jae
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Publication of MX2018009861A publication Critical patent/MX2018009861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto novedoso de tiofeno 2,3,5-sustituido que tiene actividad inhibidora contra cinasas, un agente anticancerígeno que incluye el compuesto como ingrediente activo, y un método para preparar el compuesto.
MX2018009861A 2016-02-16 2017-02-16 Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. MX2018009861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160017991 2016-02-16
PCT/KR2017/001715 WO2017142325A1 (ko) 2016-02-16 2017-02-16 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물

Publications (1)

Publication Number Publication Date
MX2018009861A true MX2018009861A (es) 2019-06-06

Family

ID=59626142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009861A MX2018009861A (es) 2016-02-16 2017-02-16 Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.

Country Status (16)

Country Link
US (1) US10442796B2 (es)
EP (1) EP3418275B1 (es)
JP (2) JP6749422B2 (es)
KR (3) KR20170096599A (es)
CN (1) CN108884066B (es)
AU (1) AU2017221707B2 (es)
BR (1) BR112018016729B1 (es)
CA (1) CA3014740C (es)
DK (1) DK3418275T3 (es)
ES (1) ES2866890T3 (es)
HK (1) HK1258053A1 (es)
MX (1) MX2018009861A (es)
NZ (1) NZ745210A (es)
PT (1) PT3418275T (es)
RU (1) RU2724957C2 (es)
WO (1) WO2017142325A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3418275T3 (da) * 2016-02-16 2021-05-10 Korea Inst Sci & Tech Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer
WO2019231220A1 (ko) * 2018-05-30 2019-12-05 (주)파로스아이비티 2,3,5-치환된 싸이오펜 화합물의 유방암 예방, 개선 또는 치료 용도
US20210205289A1 (en) * 2018-05-30 2021-07-08 Pharos Ibio Co., Ltd. Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR102578970B1 (ko) * 2020-03-04 2023-09-15 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도
US20230293507A1 (en) * 2020-03-04 2023-09-21 Pharos Ibio Co., Ltd Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
KR102535842B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도
WO2023063784A1 (ko) * 2021-10-14 2023-04-20 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361759T1 (de) * 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
NZ540161A (en) * 2002-10-30 2008-03-28 Vertex Pharma Compositions useful as inhibitors of rock and other protein kinases
JP2005064770A (ja) * 2003-08-11 2005-03-10 Ricoh Co Ltd 情報処理装置、認証装置、外部装置、証明情報取得方法、認証方法、機能提供方法、証明情報取得プログラム、認証プログラム、機能提供プログラム及び記録媒体
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1732920B1 (en) * 2004-01-05 2011-03-09 AstraZeneca AB Thiophene derivatives as chk 1 inhibitors
AU2005228899A1 (en) * 2004-03-30 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Substituted thiophene derivatives as anti-cancer agents
JP2008534565A (ja) * 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
KR100703622B1 (ko) * 2005-10-26 2007-04-06 삼성전기주식회사 캡 방식의 카메라 모듈
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
WO2012098416A1 (en) * 2011-01-21 2012-07-26 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
DK3418275T3 (da) * 2016-02-16 2021-05-10 Korea Inst Sci & Tech Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer

Also Published As

Publication number Publication date
RU2724957C2 (ru) 2020-06-29
HK1258053A1 (zh) 2019-11-01
AU2017221707A1 (en) 2018-08-30
US10442796B2 (en) 2019-10-15
EP3418275B1 (en) 2021-03-17
RU2018130703A3 (es) 2020-03-17
DK3418275T3 (da) 2021-05-10
JP2019504900A (ja) 2019-02-21
KR20190035671A (ko) 2019-04-03
WO2017142325A1 (ko) 2017-08-24
EP3418275A1 (en) 2018-12-26
US20190047993A1 (en) 2019-02-14
KR20170096599A (ko) 2017-08-24
CN108884066B (zh) 2021-08-24
ES2866890T3 (es) 2021-10-20
CA3014740A1 (en) 2017-08-24
KR101965326B1 (ko) 2019-04-03
NZ745210A (en) 2019-08-30
EP3418275A4 (en) 2019-07-17
AU2017221707B2 (en) 2019-10-03
KR20180136425A (ko) 2018-12-24
RU2018130703A (ru) 2020-03-17
CN108884066A (zh) 2018-11-23
PT3418275T (pt) 2021-04-22
CA3014740C (en) 2021-06-01
KR102069730B1 (ko) 2020-01-23
JP6749422B2 (ja) 2020-09-02
BR112018016729A2 (pt) 2018-12-26
BR112018016729B1 (pt) 2023-10-24
JP2020143118A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
NZ745210A (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
PH12020550622A1 (en) Kras g12c inhibitors
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EP3608321A4 (en) 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS A PROTEINKINASE INIBITOR
MY185500A (en) Macrocylic pyridine derivatives
MY185491A (en) Macrocylic pyrimidine derivatives
WO2016085221A3 (ko) 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
MY176401A (en) Novel disubstituted 1,2,4-triazine compound
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
EP4327880A3 (en) Solid state form of ribociclib succinate
EP4066835A4 (en) USE OF A COMPOSITION FOR INCREASE ANTI-CANCER EFFECT HAVING A GAMMA INHIBITOR AS THE ACTIVE INGREDIENT
WO2011159137A3 (ko) 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
NZ738197A (en) Antihypertensive agent
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
WO2011149288A2 (ko) 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물
EP4029862A4 (en) CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
EP3327000A4 (en) NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION WITH A TSP1 PROTEIN INHIBITOR AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF FABRY DISEASE